Knockdown of CircCRIM1 Inhibits HDAC4 to Impede Osteosarcoma Proliferation, Migration, and Invasion and Facilitate Autophagy by Targeting MiR-432-5p
Overview
Authors
Affiliations
Background: Circular RNAs (circRNAs) serve for a genre of considerable modulatory molecules that have been largely researched in human cancers. However, the contribution of circRNA cysteine-rich transmembrane bone morphogenetic protein regulator 1 (circCRIM1) to osteosarcoma (OS) is completely unclear.
Methods: All the RNA levels were examined via quantitative real-time polymerase chain reaction (qRT-PCR). Cellular proliferation and migration/invasion were, respectively, analyzed using 3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyl tetrazolium bromide (MTT) assay and transwell assay. The determination of all protein expression was administrated by Western blot. Dual-luciferase reporter assay was used for proving the target combination. The exploration of circCRIM1 in vivo was performed by xenograft assay.
Results: In OS tissues and cells, circCRIM1 was differentially up-regulated. Functionally, cell proliferation, migration and invasion were suppressed while autophagy was promoted after circCRIM1 was down-regulated in OS cells. Mechanistically, mircoRNA-432-5p (miR-432-5p) was a miRNA target of circCRIM1 and the inhibitory effect of circCRIM1 knockdown on OS progression was achieved by targeting miR-432-5p. Moreover, histone deacetylase 4 (HDAC4) was a downstream gene of miR-432-5p and circCRIM1 targeted miR-432-5p to up-regulate HDAC4 level. MiR-432-5p inhibited proliferation, migration, and invasion but enhanced autophagy of OS cells through down-regulating HDAC4. In vivo, knockdown of circCRIM1 decreased OS growth via acting on the miR-432-5p/HDAC4 axis.
Conclusion: Our findings elucidated the oncogenic function of circCRIM1 in OS via the regulation of the miR-432-5p/HDAC4 axis, affording a novel view about how circRNA participated in OS development.
Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis.
Shang J, Zhao F, Xie L, Wang Y, Li B, Jin C Open Med (Wars). 2024; 19(1):20241080.
PMID: 39655055 PMC: 11627063. DOI: 10.1515/med-2024-1080.
Lima F, Fernandes F, Almeida D, Carvalho A, Almeida V, Cavalcante G Asian Pac J Cancer Prev. 2024; 25(4):1195-1203.
PMID: 38679978 PMC: 11162731. DOI: 10.31557/APJCP.2024.25.4.1195.
Han Z, Luo W, Shen J, Xie F, Luo J, Yang X Front Cell Dev Biol. 2024; 12:1284934.
PMID: 38481525 PMC: 10936223. DOI: 10.3389/fcell.2024.1284934.
Tang S, Cai L, Wang Z, Pan D, Wang Q, Shen Y Cancer Innov. 2023; 2(6):463-487.
PMID: 38125767 PMC: 10730008. DOI: 10.1002/cai2.50.
CircCRIM1 suppresses osteosarcoma progression via sponging miR146a-5p and targeting NUMB.
Chen J, Hei R, Chen C, Wu X, Han T, Bian H Am J Cancer Res. 2023; 13(8):3463-3481.
PMID: 37693139 PMC: 10492126.